• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Liver cancer screening in high-risk populations.高危人群的肝癌筛查
Hepat Oncol. 2016 Jan;3(1):13-18. doi: 10.2217/hep.15.35. Epub 2015 Nov 30.
2
Chronic hepatitis B virus infection in Asian countries.亚洲国家的慢性乙型肝炎病毒感染
J Gastroenterol Hepatol. 2000 Dec;15(12):1356-61. doi: 10.1046/j.1440-1746.2000.0150121356.x.
3
Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.慢性乙型肝炎病毒感染患者的非肝硬化肝细胞癌。
J Hepatol. 2017 Feb;66(2):355-362. doi: 10.1016/j.jhep.2016.09.013. Epub 2016 Sep 28.
4
Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.验证 AFP 模型作为预测病毒肝炎相关性肝硬化患者 HCC 复发的指标,这些患者因 HCC 已接受肝移植。
J Hepatol. 2017 Mar;66(3):552-559. doi: 10.1016/j.jhep.2016.10.038. Epub 2016 Nov 27.
5
Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.经FibroScan检测的亚肝硬化肝硬度与乙肝相关肝硬化患者肝细胞癌风险较低相关。
Hepatol Int. 2017 May;11(3):268-276. doi: 10.1007/s12072-017-9789-y. Epub 2017 Feb 21.
6
Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.开发一种评分系统,以预测亚洲慢性乙型肝炎抗病毒治疗患者的肝细胞癌。
J Hepatol. 2018 Aug;69(2):278-285. doi: 10.1016/j.jhep.2018.02.032. Epub 2018 Mar 16.
7
Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.肝细胞癌肝硬化监测:系统评价与经济分析
Health Technol Assess. 2007 Sep;11(34):1-206. doi: 10.3310/hta11340.
8
Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area.某流行地区2293例慢性乙型肝炎患者的肝细胞癌筛查与监测
World J Gastroenterol. 2016 Sep 14;22(34):7806-12. doi: 10.3748/wjg.v22.i34.7806.
9
Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.与肝炎病毒相关肝硬化患者肝细胞癌发生相关的临床和病理因素:一项长期随访研究
Clin Oncol (R Coll Radiol). 2007 Apr;19(3):197-203. doi: 10.1016/j.clon.2006.12.005. Epub 2007 Jan 18.
10
The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection.肝细胞癌风险预测评分在北美的慢性乙型肝炎感染患者人群中的适用性。
Gut. 2016 Aug;65(8):1347-58. doi: 10.1136/gutjnl-2014-309099. Epub 2015 Apr 30.

引用本文的文献

1
Temporal trends of incidence, mortality, and survival of liver cancer during 2011-2020 in Fujian Province, Southeast China.2011 - 2020年中国东南部福建省肝癌发病率、死亡率及生存率的时间趋势
Arch Public Health. 2024 Dec 4;82(1):233. doi: 10.1186/s13690-024-01462-7.

本文引用的文献

1
The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection.肝细胞癌风险预测评分在北美的慢性乙型肝炎感染患者人群中的适用性。
Gut. 2016 Aug;65(8):1347-58. doi: 10.1136/gutjnl-2014-309099. Epub 2015 Apr 30.
2
Development of risk scoring system for stratifying population for hepatocellular carcinoma screening.开发用于分层人群进行肝细胞癌筛查的风险评分系统。
Hepatology. 2015 Jun;61(6):1934-44. doi: 10.1002/hep.27610. Epub 2015 Apr 13.
3
Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model.肝硬化患者肝细胞癌风险预测:ADRESS-HCC 风险模型。
Cancer. 2014 Nov 15;120(22):3485-93. doi: 10.1002/cncr.28832. Epub 2014 Jul 16.
4
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.恩替卡韦治疗不能消除慢性乙型肝炎患者肝细胞癌的风险:风险评分在白种人中作用有限。
Gut. 2015 Aug;64(8):1289-95. doi: 10.1136/gutjnl-2014-307023. Epub 2014 Jul 10.
5
Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis.基于肝脏硬度的慢性乙型肝炎病毒感染患者肝细胞癌预测模型:与组织学纤维化的比较
Liver Int. 2015 Mar;35(3):1054-62. doi: 10.1111/liv.12621. Epub 2014 Jul 8.
6
A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.一种新的基于实验室的算法,用于预测丙型肝炎和肝硬化患者发生肝细胞癌的风险。
Gastroenterology. 2014 May;146(5):1249-55.e1. doi: 10.1053/j.gastro.2014.01.045. Epub 2014 Jan 23.
7
Diabetes mellitus is associated with hepatocellular carcinoma: a retrospective case-control study in hepatitis endemic area.糖尿病与肝细胞癌相关:肝炎流行地区的一项回顾性病例对照研究。
PLoS One. 2013 Dec 26;8(12):e84776. doi: 10.1371/journal.pone.0084776. eCollection 2013.
8
Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.基于肝硬度的慢性乙型肝炎患者肝细胞癌风险评分优化。
J Hepatol. 2014 Feb;60(2):339-45. doi: 10.1016/j.jhep.2013.09.029. Epub 2013 Oct 12.
9
Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy.基于干扰素治疗的慢性丙型肝炎患者发生肝细胞癌的临床指导风险预测。
Br J Cancer. 2013 Oct 29;109(9):2481-8. doi: 10.1038/bjc.2013.564. Epub 2013 Oct 1.
10
Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.慢性乙型肝炎患者长期肝硬化和肝细胞癌风险的预测模型:整合宿主和病毒特征的风险评分。
Hepatology. 2013 Aug;58(2):546-54. doi: 10.1002/hep.26385.

高危人群的肝癌筛查

Liver cancer screening in high-risk populations.

作者信息

Sherman Morris

机构信息

Department of Medicine, University of Toronto, ON M5S 1A8, Canada.

出版信息

Hepat Oncol. 2016 Jan;3(1):13-18. doi: 10.2217/hep.15.35. Epub 2015 Nov 30.

DOI:10.2217/hep.15.35
PMID:30191024
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6095323/
Abstract

Patients with liver disease have a risk of developing hepatocellular carcinoma (HCC), but the risk varies between different diseases and is also different according to several other variables, such as age, type of underlying liver disease and severity of disease. Several risk scores have been developed to more adequately quantitate HCC risk in individual patients. Each risk score is applicable to a specific population (chronic hepatitis B or C, patients on the transplant list, cirrhosis in general, and so on). Most publications on risk scores do not provide clear guidance as to what level of measured risk is sufficient to trigger surveillance.

摘要

肝病患者有发生肝细胞癌(HCC)的风险,但不同疾病的风险有所不同,并且根据其他几个变量(如年龄、潜在肝病类型和疾病严重程度)也存在差异。已经开发了几种风险评分来更充分地量化个体患者的HCC风险。每个风险评分适用于特定人群(慢性乙型或丙型肝炎、移植名单上的患者、一般肝硬化患者等)。大多数关于风险评分的出版物并未就测量的风险达到何种水平足以触发监测提供明确指导。